A MULTICENTER, OPEN-LABEL TRIAL TO ASSESS SUBJECT PREFERENCE OF PARCOPA, CARBIDOPA/LEVODOPA ORALLY DISINTEGRATING TABLETS, COMPARED TO CONVENTIONAL CARBIDOPA/LEVODOPA TABLETS IN SUBJECTS WITH STABLE PARKINSON'S DISEASE: